29th October – 4th November
Monday 29th October
AstraZeneca is collaborating with Medicines Discovery Catapult for Acoustic Mist Ionisation Mass Spectrometry
AMI-MS introduces a twenty-fold improvement in throughput compared to traditional mass spectrometry. AMI use sound energy to introduce the sample into the detector rather than via a needle. A mist of charged droplets are lifted from the surface of a sample into the mass spectrometer. This method is contactless and contamination free with a sample being able to be analyzed every three seconds.
“This deal will allow small, medium enterprises (SME) access to the state-of-the-art bio analytical technology through research partnerships with Catapult. The collaboration will allow AstraZeneca to further unlock the potential of Acoustic Mist Ionisation Mass Spectrometry (AMI-MS) by accessing Medicines Discovery Catapults technical expertise” said the organisation.
Tuesday 30th October
The Accelerated Access Collaborative (ACC) has announced its first Rapid Uptake Products for the NHS
The ACC has announced that Roche's Diagnostic tests for suspected pre-eclampsia and heart attacks have been recognized and have been selected among the seven Rapid Uptake products for the NHS. The ACC brings together leaders from the Government, NHS and life sciences industry to drive forward innovation in the NHS. With work towards recognizing ideas that would be the most transformative for the NHS.
Roche's diagnostic tests have been recommended by NICE for use in clinical practices. The tests are simple blood tests that help clinicians quickly decide on the right course of action. These tests can also help alleviate pressure on the NHS resources by focusing efforts where they are most needed.
Wednesday 24th October
Medidata has teamed up with Pharm-OlamMedidata and Pharm-Olam have signed a new five-year deal to unify operational systems supporting study execution on Medidata Cloud. Pharm-Olam used to use multiple systems, leading to duplications of data when needed which would then require further integration later. With the introduction of Medidata, Pharm-Olam will be able to have all its data unified. It will help reduce costs for Pharm-Olam and provide better services to its customers.
Thursday 1st November
Gilead experiences dip in revenue but continues to raise outlook for the rest of the year
Gilead’s revenue beat expectations for the third quarter, despite experiencing a loss from last years results, leading the company to boost its earnings expectations for the rest of the year. Total revenues were $5.6 billion in 2018 compared to $6.5 billion in 2017. While Net income was $2.1 billion compared to $2.7 billion. Total product sales for the third quarter of 2018 were $5.5 billion compared to $6.4 billion for the same period in 2017.
With the global shutdown that has occurred due to COVID-19, its presence has caused long-lasting effects in all aspects of our lives and t...
UnaCom Product News Round Up ...
The Competitions Market Authority (CMA) has raised concerns that the proposed merger between Illumina and Pacific BioSciences will lea...
This would be the first federal trial for the case in the US, despite attempts from J&J to avoid this scenario as it tried to negotiat...
After continuous delay there finally seems to be progress for the clearance of this $4.3bn deal by the FTC. According to reports made by...
AZ’s lung cancer drug Tagrissio has already established itself as AZ top selling medicine, in the third quarter it grew sales by over 13.6...